Taisho Pharmaceutical Buys Back Shanghai Dazhengli Health Care Shares
This article was originally published in PharmAsia News
Executive Summary
Japanese firm Taisho Pharmaceutical, a majority stakeholder of Shanghai Dazhengli Health Care, has purchased the latter's 15 percent shares held by Guan Shen Yuan (Group) at RMB 14.7994 million. Taisho Pharmaceutical, the world's leading OTC manufacturer, set up Shanghai Dazhengli Health Care in 1997 to promote and sell its Libogen products in China. Shanghai Dazhengli can output more than 20 million bottles of Lipovitan D nutrient drink annually, with China being Taisho's best overseas market. Taisho has been trying to expand its production capacity and sales in the country, with major markets extending from Shanghai to the north, northeast and south of China. Analysts observe that the buy-back indicates Taisho's confidence in the market. (Click here for more - Chinese Language)